


Summary

Name	uPA/PLAU/Urokinase-Type Plasminogen Activator
Purity	Greater than 95% as determined by reducing SDS-PAGE
Endotoxin level	<1 EU/µg as determined by LAL test.
Construction	Recombinant Human Urokinase-Type Plasminogen Activator is produced by our Mammalian expression system and the target gene encoding Ser21- Leu431 is expressed with a 6His tag at the C-terminus.
Accession #	P00749
Host	Human Cells
Species	Human
Predicted Molecular Mass	47.41 KDa
Formulation	Supplied as a 0.2 μ m filtered solution of 20mM HEPES, 2mM CaCl2, 10% Glycerol, pH 7.4.
Shipping	The product is shipped on dry ice/polar packs. Upon receipt, store it immediately at the temperature listed below.
Stability & Starage	
Stability&Storage	Store at \leq -70°C, stable for 6 months after receipt. Store at \leq -70°C, stable for 3 months under sterile conditions after opening. Please minimize freeze-thaw cycles.

SDS-PAGE image



Background

Alternative Names	Urokinase-Type Plasminogen Activator; U-Plasminogen Activator; uPA; PLAU
Background	Recombinant Human Urokinase-Type Plasminogen Activator is a serine protease, which specifically cleaves the zymogen plasminogen to form the active enzyme



plasmin. Urokinase-Type Plasminogen Activator is a potent marker of invasion and metastasis in many human cancers associated with breast, colon, stomach, bladder, brain, ovary and endometrium. Human Urokinase-Type Plasminogen Activator is initially synthesized as 431 amino acid precursor with a N-terminal signal peptide residues. The single chain molecule is processed into a disulfide-linked two-chain molecule. There exists two forms A chain, the long A chain contains an EGF-like domain that is responsible for binding of the uPA receptor. The B chain corresponds to the catalytic domain.

Note

For Research Use Only, Not for Diagnostic Use.